Pterostilbene Inhibits Human Multiple Myeloma Cells via ERK1/2 and JNK Pathway In Vitro and In Vivo

CAS Key Laboratory of Receptor Research, Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China

College of Life Science and Technology, Tongji University, Shanghai 200092, China

Authors to whom correspondence should be addressed.

^†

These authors contributed equally to this work.

Academic Editor: Gregor Drummen

Int. J. Mol. Sci. 2016, 17(11), 1927; https://doi.org/10.3390/ijms17111927

Received: 22 September 2016 / Revised: 6 November 2016 / Accepted: 10 November 2016 / Published: 17 November 2016

(This article belongs to the Section Biochemistry)

View Full-Text Download PDF

Browse Figures

Citation Export

Abstract

Multiple myeloma (MM) is the second most common malignancy in the hematologic system, which is characterized by accumulation of plasma cells in bone marrow. Pterostilbene (PTE) is a natural dimethylated analog of resveratrol, which has anti-oxidant, anti-inflammatory and anti-tumor properties. In the present study, we examined the anti-tumor effect of PTE on MM cell lines both in vitro and in vivo using the cell counting kit (CCK)-8, apoptosis assays, cell cycle analysis, reactive oxygen species (ROS) generation, JC-1 mitochondrial membrane potential assay, Western blotting and tumor xenograft models. The results demonstrated that PTE induces apoptosis in the H929 cell line and causes cell cycle arrest at G0/G1 phase by enhancing ROS generation and reducing mitochondrial membrane potential. The anti-tumor effect of PTE may be caused by the activation of the extracellular regulated protein kinases (ERK) 1/2 and c-Jun N-terminal kinase (JNK) signaling pathways. Additionally, mice treated with PTE by intraperitoneal injection demonstrated reduced tumor volume. Taken together, the results of this study indicate that the anti-tumor effect of PTE on MM cells may provide a new therapeutic option for MM patients. View Full-Text

Keywords: multiple myeloma; pterostilbene; apoptosis; cell cycle; ERK1/2; JNK

▼ Show Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

Share and Cite

MDPI and ACS Style

Xie, B.; Xu, Z.; Hu, L.; Chen, G.; Wei, R.; Yang, G.; Li, B.; Chang, G.; Sun, X.; Wu, H.; Zhang, Y.; Dai, B.; Tao, Y.; Shi, J.; Zhu, W. Pterostilbene Inhibits Human Multiple Myeloma Cells via ERK1/2 and JNK Pathway In Vitro and In Vivo. Int. J. Mol. Sci. 2016, 17, 1927. https://doi.org/10.3390/ijms17111927

AMA Style

Xie B, Xu Z, Hu L, Chen G, Wei R, Yang G, Li B, Chang G, Sun X, Wu H, Zhang Y, Dai B, Tao Y, Shi J, Zhu W. Pterostilbene Inhibits Human Multiple Myeloma Cells via ERK1/2 and JNK Pathway In Vitro and In Vivo. International Journal of Molecular Sciences. 2016; 17(11):1927. https://doi.org/10.3390/ijms17111927

Chicago/Turabian Style

Xie, Bingqian, Zhijian Xu, Liangning Hu, Gege Chen, Rong Wei, Guang Yang, Bo Li, Gaomei Chang, Xi Sun, Huiqun Wu, Yong Zhang, Bojie Dai, Yi Tao, Jumei Shi, and Weiliang Zhu. 2016. "Pterostilbene Inhibits Human Multiple Myeloma Cells via ERK1/2 and JNK Pathway In Vitro and In Vivo" International Journal of Molecular Sciences 17, no. 11: 1927. https://doi.org/10.3390/ijms17111927

Find Other Styles

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Abstract views Pdf views Html views

Article Menu

Pterostilbene Inhibits Human Multiple Myeloma Cells via ERK1/2 and JNK Pathway In Vitro and In Vivo

Abstract

Share and Cite

Article Metrics

Article Access Statistics

Article Access Map by Country/Region

Further Information

Guidelines

MDPI Initiatives

Follow MDPI